Merck KGaA secures exclusive worldwide rights to anti PD-L1 antibody Bavencio.
Merck KGaA announced it has strengthened its Oncology franchise by regaining exclusive worldwide rights to develop, manufacture, and commercialize anti-programmed death ligand-1 (PD-L1) antibody Bavencio (avelumab) following the termination of their Alliance agreement with Pfizer.
Reflecting a long-held interest of Merck KGaA (Merck), effective June 30, 2023, Merck, through its affiliate Ares Trading S.A., will take full control of the global commercialization of Bavencio. The current profit share will be replaced by a 15% royalty to Pfizer on net sales of Bavencio. Merck and Pfizer will continue to operationalize their respective ongoing clinical trials for Bavencio and Merck will control all future research and development activities. As it is currently, product manufacturing and supply chain will remain solely with Merck, ensuring continuous and reliable access to Bavencio for patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.